You probably could in theory, its not that simple though. Trials in humans are still very limited as far as i'm aware
You need:
1. Complementary pairing that is specific enough toto target virus RNA but not be host cross reactive
2. Half life of RNAs is very short; you need a solution for that (something like a vesicular vehicle that induces gradual release?)
3. as opposed to treating inherited disease, where RNA copy numbers are stable and relatively uniform (or at least predictable by tissue), a viral infection causes extreme spikes on a cellular level of viral RNA levels and protein being produced as that particular infected cell is taken over. ultimately you have the problem of trying to apply a one-size-fits-all dosage to a massively heterogeneous landscape of cells
